Kevin Parker, Cartography Biosciences co-founder and CEO
In bid to avoid immunotherapy toxicities, Cartography charts a course toward modality-agnostic drugs
In the early days of the Covid-19 pandemic, Kevin Parker was wrapping up his PhD work on regenerative medicine and stem cell biology at Stanford …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
